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Abstract
Background: Despite current knowledge of mutations in 45 genes that can cause nonsyndromic sensorineural
hearing loss (SNHL), no unified clinical test has been developed that can comprehensively detect mutations in
multiple genes. We therefore designed Affymetrix resequencing microarrays capable of resequencing 13 genes
mutated in SNHL (GJB2, GJB6, CDH23, KCNE1, KCNQ1, MYO7A, OTOF, PDS, MYO6, SLC26A5, TMIE, TMPRSS3, USH1C).
We present results from hearing loss arrays developed in two different research facilities and highlight some of the
approaches we adopted to enhance the applicability of resequencing arrays in a clinical setting.
Results: We leveraged sequence and intensity pattern features responsible for diminished coverage and accuracy
and developed a novel algorithm, sPROFILER, which resolved >80% of no-calls from GSEQ and allowed 99.6%
(range: 99.2-99.8%) of sequence to be called, while maintaining overall accuracy at >99.8% based upon dideoxy
sequencing comparison.
Conclusions: Together, these findings provide insight into critical issues for disease-centered resequencing
protocols suitable for clinical application and support the use of array-based resequencing technology as a
valuable molecular diagnostic tool for pediatric SNHL and other genetic diseases with substantial genetic
heterogeneity.
Background
The medical evaluation of sensorineural hearing loss
(SNHL) involves a combination of non-genetic labora-
tory and radiographic tests. The former provide little
diagnostic or prognostic information [1]. Radiographic
evaluations are helpful in diagnosing temporal bone
anomalies, but are expensive and require sedation or
general anaesthesia in children [2]. Additionally, these
tests are time-consuming and stressful for the child and
family. Most recently, genetic testing of the GJB2 gene
has been added to the diagnostic evaluation. Mutations
in this gene account for about 20% of children with
nonsyndromic SNHL [3]. Recent data has demonstrated
the utility of GJB2 analysis in determining prognosis, the
best intervention, and recurrence risks to future children
and other family members [4,5]. Genetic testing can also
predict the absence or onset of a syndrome for which
the other clinical problems may not be present at birth
or early childhood (e.g. adolescent-onset blindness in
Usher syndrome). When the genetic etiology can be
determined in a large cohort of patients, it will provide
a better understanding of the genotype-phenotype corre-
lations that exist for each of the genes examined, which
could direct specific therapeutic interventions.
Beyond GJB2, it is uncertain what genetic mutations
are the next most prevalent in patients with hearing
loss. Other genes thought to play a significant role in
childhood hearing loss include SLC26A4 [6], Usher type
1 genes (e.g. MYO7A, CDH23) [7,8] and OTOF [9],
though no studies have looked at many genes to
appreciate their relative contributions. The identification
of over 45 genes causative for SNHL now makes it
imperative to develop a high-throughput resequencing
assay. Such a technology would allow for a more
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evaluation of the etiology of hearing loss in patients.
Current technology allows for widespread screening of
only the most common genes related to SNHL (i.e.
GJB2).
Recent advances in molecular microarray technology
have made it feasible to rapidly screen DNA samples for
thousands of possible genetic mutations [10-14]. The
advantages of microarray-based screening include its
accuracy, simplicity, efficiency and cost-effectiveness
when employed on a large scale. However, call rates
among different microarray designs may vary consider-
ably [11,15,16]. While computational methods for reduc-
tion in false positives due to systematic effects have
previously been proposed [17], inadequate call coverage
is also a considerable limitation of the resequencing
array-based approach [13,15].
The efficiency of sequence-specific hybridization is
dependent on the properties of the probe and target
sequences [18]. High GC-content, presence of a nearby
SNP and cross-hybridizing sequences are known to
affect base-calling, thus limiting the capacity of rese-
quencing microarrays. It has been shown that C-rich
probes perform better than the complementary G-rich
probes [19]. Additionally, it has been reported that
nearly 80% of no-calls can be resolved by visual inspec-
tion of the intensities as one of the strands provides a
clear signature for these positions [13]. However, there
are no existing computational approaches that leverage
such sequence-specific characteristics in an attempt to
resolve GSEQ no-calls that have a distinct signature on
one strand but are still ruled no-call due to improper
hybridization on the complementary strand.
GSEQ is known to produce very few false negatives,
thus providing a highly sensitive test. However, follow-
up dideoxy sequencing for resolution of no-calls leads
to an additional variable cost, a factor which needs to be
carefully considered for clinical application of the tech-
nology. To this effect, we propose a novel algorithm for
resolution of no-calls from GSEQ. It should be noted
that the algorithm is not designed to be an alternative
to GSEQ. Instead, it provides an optional step for salva-
ging unresolved bases from GSEQ before initiating con-
firmatory dideoxy sequencing.
Our work focuses on evaluating the effectiveness of
resequencing arrays as a tool for variant detection and
discusses the impact on base-calling of adopting addi-
tional computational algorithms and laboratory proto-
cols. This study presents the results from hearing loss
arrays developed in two different research facilities and
highlights some of the approaches we adopted to
enhance the applicability of the arrays in a clinical
setting.
Results
Overall array performance
The Harvard array contained 8 genes (see Methods). Per-
formance characteristics were determined from data ana-
lyzed for a set of 26 arrays run after protocol optimization
(Table 1). The average base call rate across the 26 arrays
(654,862 bases) was 96.9% using Affymetrix GDAS 2.0.
We confirmed every variant call with dideoxy sequencing
to determine the false positive rate. On average, about 57
variants were called per array but only 28% were true var-
iants and the rest were false positives. Dideoxy sequencing
of 352,618 bases across 14 arrays was performed and the
data compared to array calls. Factoring in false negatives
and false positives, we obtained an average base call accu-
racy of 99.82% across the 14 arrays.
The Cincinnati array also contained 8 genes, 3 of
which were common to the Harvard array (see Meth-
ods). We ran 12 arrays in the pilot batch and character-
ized array performance. Base call rates for these 12
arrays (315,504 bases) ranged from 82.5% to 96.9% with
an average call rate of 91.3% using GSEQ 4.0 (Figures 1
&2). Dideoxy sequencing was performed for 296,296 of
the bases and comparison of this data with array calls
g a v eac a l la c c u r a c yo f9 9 . 2 3 %w i t hn e a r l y1 8 0f a l s e
positives per array.
Improved array performance with protocol optimization
When we compared data from Cincinnati and Harvard
arrays, the number of no-calls and false positives from
the former were found to be higher. Early data from the
Harvard arrays had shown that call rate worsened when
the fragmentation was incomplete and that the bases
most affected were those within the long range PCR frag-
ments. In addition, the reproducibility of the quantity of
product from long range PCR was less. Based upon these
two factors, the target amplification process for Cincin-
nati arrays was modified. Instead of using a combination
of long and short range PCR (54 fragments ranging from
434 to 13,282 bases in length), as was employed in the
pilot batch, all long range PCRs were converted to short
range resulting in 180 fragments ranging from 315 to 980
bases in length. The impact of using shorter PCR pro-
ducts was evaluated by comparing array data across the
two protocols (Figures 1 &2). A total of 13 arrays
(341,796 bases) were run with the optimized “short range
PCR only” protocol and an average call rate of 97.9%
(range 96.7% to 98.4%) was obtained with GSEQ (Table
1). Dideoxy sequencing was performed for 336,171 of the
bases and comparison of this data with array calls gave
an array call accuracy of 99.83%. The average number of
false positives dropped from 180 to 42 per array. The
modified protocol with shorter PCR products was then
adopted for subsequent arrays.
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Page 2 of 11Table 1 Overall array performance with and without application of sPROFILER to GDAS/GSEQ base calls.
Harvard arrays
with GDAS*
Harvard arrays with
GDAS/sPROFILER*
Cincinnati arrays
with GSEQ
Cincinnati arrays with
GSEQ/sPROFILER
Number of arrays 26 26 13 13
Bases per array 25187 25187 26292 26292
Array call rate
A 96.9% 99.6% 97.9% 99.6%
Call accuracy
B 99.82% 99.84% 99.83% 99.88%
Total false positive rate
C 0.18% (41) 0.15% (38) 0.16% (42) 0.11% (30)
Total false negative rate
D 0.0016% (0.4) 0.0031% (0.9) 0.0009% (0.2) 0.0020% (0.6)
Variant false positive rate
E 72.6% (41/57) 71.6% (38/51) 77.7% (42/54) 69.7% (30/43)
Variant false negative rate
F 2.4% (0.4/16) 4.5% (0.9/16) 1.3% (0.2/15) 3.0% (0.6/15)
No-calls
G 781 101 563 103
No. of exons to be sequenced
H/Total no.
of exons on array
153/196 52/196 150/180 68/180
Percentages are obtained by averaging individual percent values over all arrays.
A: Bases called/total bases on array
B: Correct calls/total calls
C: Wild-type bases incorrectly identified as variants/total calls * 100% (average raw # per array)
D: True variants incorrectly called wild-type/total calls * 100% (average raw # per array)
E: Wild-type bases incorrectly identified as variants/total variant calls * 100%
F: True variants incorrectly called wild-type/total true variants * 100%
G: Average number of bases not called per array
H: Number of exons that need follow-up sequencing to interrogate no-calls or variant calls
*: 14 Harvard arrays with full dideoxy sequencing results were used for determination of false negatives and overall accuracy. However, no-calls and variant calls
across all 26 Harvard arrays were used for call rates and false positive rates.
Figure 1 Improvement in array call rates with protocol optimization and application of sPROFILER to GSEQ calls.( d a t as h o w nf o r
Cincinnati arrays). Data is separated into two categories based upon protocol (short and long range PCR vs. short range only PCR) and then
arranged in ascending order of GSEQ call rates.
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Through dideoxy sequencing, we identified four cases
with at least one insertion or deletion (35delG/35delG,
35delG/167delT, and M1V/167delT in GJB2 and homo-
zygous 1180_1187del8ins(b-sat) in TMPRSS3), of which
2 had been previously reported and therefore had
probes tiled on the array for their detection (GJB2
35delG and 167delT) (Additional file 1). We analyzed
array data to look for no-calls or variant calls in the vici-
nity of the indel sites but did not observe any such pat-
terns for the 35delG and 167delT alleles. It should be
noted that the local high GC-content surrounding the
35delG (stretch of 5 Gs; probe GC 56%) and the
167delT (stretch of 4 Cs; probe GC 64%) would be
expected to make detection extremely difficult. On the
other hand, there was a continuous stretch of 13 no-
calls and a variant call spanning the deleted bases of the
TMPRSS3 gene that led to the detection of the muta-
tion. We also analyzed raw feature intensities within
fragments to see if indels cause degradation in intensi-
ties surrounding the variant site. We observed lower
peak intensities surrounding the TMPRSS3 mutation but
did not find such evidence for either of the single base
GJB2 deletions (data not shown). GDAS/GSEQ are cur-
rently not designed for identifying indels so their low
detection rate was an expected observation.
Differential impact of high C-content and G-content on
probe performance
In agreement with previously reported findings [19,20],
we observed that an increase in probe G- and C-con-
tents have differential impact on performance. We used
complementary feature quartets to determine intensities
associated with the C- or G-content of a probe. Intensity
characteristics varied differently with respect to an
increase in C- or G-content and average peak intensity
was affected more severely by a high G-content than by
an equally high C-content (Figure 3a). In order to assess
Figure 2 Performance improvement with protocol optimization; array sensitivity and specificity with application of sPROFILER to
GSEQ calls. (data shown for Cincinnati arrays). Data is arranged in the same patient ID order as figure 1. (a) False positive calls with and
without protocol optimization/sPROFILER. No-calls and positive calls were processed for the first 12 chips (short and long range PCR protocol)
while only no-calls were processed for the remaining 13 chips (short range only PCR protocol). No-calls were converted to wild-type, left as no-
call, or were assigned a variant call. Chips that were analyzed only for no-calls may show an increase in false positive rate due to conversion of a
fraction of no-calls to variant calls, some of which are not true variants. (b) False negative calls with and without protocol optimization/
sPROFILER represented as a portion of total true variants.
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effect of stretches of Gs (G-stacks) on probe perfor-
mance [21], we compared hybridization intensities
among probes with the same G-content grouped based
on the presence or absence of G-stretches (≥ 4G si na
continuous stretch). For the same G-content, probes
with G-stretches produced lower peak intensities than
probes with C-stretches or without any stretches of Gs
or Cs (Figure 3b).
Overall array performance with sPROFILER
sPROFILER was only used on no-calls from GDAS/
GSEQ. Examined bases were called wild-type based on
single-strand evidence or were left as no-calls depending
upon the feature intensity profile. Base calls were subse-
quently compared against GSEQ and dideoxy sequen-
cing calls. Table 1 and Figures 1 &2 provide detailed
comparison of call rates, number of false positives and
false negatives before and after analyzing GSEQ calls
with sPROFILER. For Cincinnati arrays run with short
and long range PCR fragments, the average call rate
increased to 96.7% (99.82% call accuracy). The average
number of no-calls dropped from 2350 to 902 per array
and the number of false positives dropped from 180 to
44 bases per array. Improvement was obtained at the
cost of incorrectly assigning an additional 0.38 true var-
iants per array as wild-type. For the optmized Cincinnati
arrays, average call rate increased to 99.6% (range 99.5%
Figure 3 Differential impact of high probe G-content and C-content on probe performance; G-richness of a probe has a more severe
impact on hybridization intensity than C-richness and G-stretches degrade peak intensity. (a) Peak feature intensity versus probe G-
content and C-content. (b) Peak feature intensity for probes with same G-content grouped based on presence of G-stretch, C-stretch and no
continuous stretches. Error bars represent one standard deviation.
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calls dropped from 563 to 103 (Table 1). The number of
false positives dropped from 42 to 30 per array with the
application of filters to screen variant calls based on low
quality scores and the number of no-calls and variant
calls in the vicinity. Improvement was achieved at the
cost of an additional 0.4 false negative per array. We
also calculated the number of exons per array that
would need to be interrogated with dideoxy sequencing
in order to resolve no-calls and confirm positive calls.
After processing GSEQ calls with sPROFILER, the aver-
age number of exons to be sequenced in order to clarify
no-calls and confirm variants dropped from 150 (range
132 to 165) to 68 (range 52 to 82) per array.
When using sPROFILER on the Harvard arrays, the
average call rate increased from 96.9% to 99.6% and
number of no-calls dropped from 781 to 101 per array
(Table 1). False positive calls could be reduced from 41
to 38 per array with the filters for false positive calls. An
additional 0.4 variants were falsely called wild-type using
the algorithm. Because all no-calls are followed up by
dideoxy sequencing, the implementation of the sPROFI-
LER resulted in substantially fewer exons (average of
153 down to 52) needing follow-up.
Clinical sensitivity of arrays
A detailed list of all variants and associated frequencies
in the patient cohorts and control populations is
included in Additional file 1. A total of 411 true variants
were detected across 26 Harvard arrays, out of which, 10
were called wildtype by GDAS (Table 2). Interestingly,
the 10 missed variants represent a single common SNP
(MYO7A 4755T>C) seen in 10 different arrays. As such,
it appears that this single substitution may be proble-
matic. The basis of the poor sensitivity for this variant
did not appear to be overall high GC-content, which
was 52%, nor a local G/C stretch (only one adjacent
base was a G). Of the 411 variants, 44 represent rare
variants, many of potential clinical significance. None of
these were missed by the array, although 12 were
assigned no-calls. Of the 192 true variants identified
across the 13 optimized Cincinnati arrays, 3 synon-
y m o u sv a r i a n t s( CDH23 2761C>T, KCNQ1 1185C>T,
MYO7A 4831C>T) were called wild-type by GSEQ
(Table 2). The CDH23 and MYO7A variants were found
to lie within a G/C stretch with probe GC-contents of
68% and 52% respectively but the KCNQ1 variant was
not associated with high GC-content or a G/C stretch.
After excluding synonymous and/or common variants,
18/37 patients examined by the Cincinnati array and 9/
24 patients examined on the Harvard array had at least
one variant of potential or likely clinical significance
(excludes two cases known to have GJB2 biallelic muta-
tions). See Additional file 1 for a full list of all variants
found on a per patient basis. To further assess the likeli-
hood that each variant may be disease-causing, efforts
are currently underway to examine these variants in
further control studies and using in silico algorithms to
predict protein impact. After these studies are com-
pleted, variants with potential clinical significance will
be confirmed in a CLIA environment with results
returned to patients under an IRB approved protocol.
Discussion
Serial molecular techniques (e.g., direct sequencing, sin-
gle-strand conformation analysis, denaturing gradient
gel electrophoresis and denaturing high-performance
liquid chromatography) have been employed for detec-
tion of mutations associated with disorders showing
high genetic and allelic heterogeneity but they can be
laborious requiring high turnaround times and show lit-
t l ed i f f e r e n c ei nt h e i rd i r e c tc o s t sp e rb a s e ,w h i c ha r e
high [12]. Conventional serial methods can be especially
ineffective for screening large genes without definite hot
spots for disease-associated mutations [10]. Although
new advancements in next generation sequencing will
soon replace all large scale sequencing platforms, these
technologies are still too costly for medium size applica-
tions of targeted disease sequencing. High-density oligo-
nucleotide microarrays provide an efficient and
economically competitive method for genetic screening
of heterogeneous disorders by allowing parallel rese-
quencing of multiple genes in a single experiment. Since
the first study reporting detection of known genomic
variants using oligonucleotide arrays [22], several others
have been published describing the principles of rese-
quencing array technology [18,20,23,24] and its applica-
tion for genotyping in prokaryotes and eukaryotes
[10-14,25-27].
We developed two resequencing microarrays contain-
ing 13 unique genes implicated in nonsyndromic SNHL.
Array base calls were compared to dideoxy sequencing
to determine accuracy. Through optimization of proto-
cols and data analysis methods, similar high-quality per-
formance measures could be achieved for microarrays
developed at two independent research facilities and
containing different sets of genes.
The critical performance characteristics we attempted
to understand and optimize are call rate, sensitivity and
specificity. Affymetrix GSEQ is an upgraded version of
the GDAS base-calling software and offers some addi-
tional features as described in the GSEQ technical data-
sheet http://www.affymetrix.com/support/technical/
datasheets/gseq_datasheet.pdf. However, they both
employ a base-calling algorithm built upon the adaptive
background genotyping-calling scheme (ABACUS)
developed by Cutler and colleagues [20]. GDAS and
GSEQ produce few false negatives because these
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False positives or no-calls do not represent a lack of test
sensitivity when they are followed up by dideoxy
sequencing; however, they compromise the cost-effec-
tiveness of the technology if a large amount of sequen-
cing is required. In our hands, the cost reduction is
roughly a 25%-50% reduction compared to traditional
capillary sequencing when thorough follow-up is
employed to resolve all variant calls and rare no-calls.
The exact reduction depends on the degree of multi-
plexing employed in the up-front PCR step and the
amount of follow-up sequencing that is needed. The lat-
ter factor is unique to each test depending on the
sequences included, PCR robustness, the amount of
DNA variation in the regions tested and degree of bioin-
formatics and test optimization that has been achieved.
It has previously been suggested that large PCR ampli-
cons do not hybridize efficiently to immobilized probes
possibly due to steric constraints on the approach of the
target DNA [28] and this finding has been taken into
consideration during design of nucleic acid amplification
strategies [29]. Optimizing the target amplification pro-
c e s st oi n c l u d eo n l ys h o r tr a n g eP C Ri m p r o v e dt h e
overall array performance in the Cincinnati arrays, thus
providing further evidence for the relationship between
PCR amplicon length and hybridization efficiency. It
should be noted that the data generated by the Harvard
arrays was based upon a combination of short range
and long range PCR. However, the Harvard group has
also discontinued use of long range PCR in subsequently
developed array-based sequencing tests. This is because
the efforts needed to continually optimize the fragmen-
tation of long range PCR fragments and the additional
limitations caused by diminished DNA quantity and
variable amplification efficiency in long range PCR do
not outweigh the benefits. For most nuclear genes with
dispersed exons, only one to a handful of exons can be
combined into a long range PCR reaction limiting the
efficiency gained by this approach. In contrast, amplifi-
cation of long stretches of contiguous interrogated
DNA, such as that present in the mitochondrial genome,
enables the highest efficiency savings for long-range
PCR approaches.
Average call rates of 96.9% and 97.7% for all of Har-
vard arrays and the optimized Cincinnati arrays respec-
tively were achieved using GDAS/GSEQ. Previous
resequencing array-based studies [10-14] have reported
call rates ranging from 93.5% to 98% with GDAS/GSEQ.
While our call rates are within the high end of reported
ranges, a large percentage (~80%) of the tiled exons
required sequencing to follow-up on ambiguous calls,
representing a limitation to clinical application of the
technology under the current methodologies.
While it is well known that the GC-content of a probe
can impact hybridization http://www.affymetrix.com/
support/technical/technotes/customseq_arraybase_tech-
note.pdf, [11] C-rich probes perform better than G-rich
probes for the identical site when complementary strand
quartets are compared [19] and fluorescence intensity
declines with G-richness of a probe [20]. Additionally,
bases within the G-stretch of a probe produce lower
peak intensities, especially for stretches with ≥ 4c o n t i n -
uous Gs. It has previously been suggested that probes
with multiple Gs in a row (G-stacks) tend to have
higher cross-hybridization signals possibly caused by for-
mation of G-quartets due to multiplex binding [21].
Table 2 Breakdown of validated variant calls across Cincinnati and Harvard arrays
Harvard (26 arrays) Cincinnati (13 arrays)
Total Per array average Total Per array average
Total variants 411 16 192 15
Total unique variants 50 16 61 15
Common variants detected
Correctly called 292 11 141 11
No call 57 2.2 23 1.8
Missed call (het vs. hom) 8 0.3 10 0.8
Called wild-type 10
A 0.4 0 0
Rare variants detected (1 case)
Correctly called 30 1.2 10 0.8
No call 12 0.5 5 0.4
Missed call (het vs. hom) 2 0.1 0 0
Called wild-type 00 3
B 0.2
A: All 10 wild-type calls (false negatives) were due to a single repeatedly miscalled common benign variant in MYO7A (4755T>C; S1585S).
B: False negatives were from CDH23 (2761C>T, L921L), MYO7A (4831C>T, L1611L) and KCNQ1 (1185C>T, F395F)
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interrogated with G-rich probes may show stronger sig-
nal on the complementary strand employing C-rich
probes. By applying additional computer algorithms
(sPROFILER) to reduce GDAS/GSEQ no-calls by utiliz-
ing a distinct signal on either strand, 86% and 82% of
the no-calls could be resolved for Harvard and Cincin-
nati arrays respectively while maintaining overall accu-
racy at ≥99.8%.
Mutations in GC-rich regions have previously been
reported to be missed [13]. We also observed that var-
iants that could be correctly identified were associated
with lower GC-content probes as compared to those
that were missed (Additional file 1). Adjusting probe
length and positioning a known variable base at either
end of the probe have been suggested to improve var-
iant detection in GC-rich regions [13,30,27].
Small indels constitute nearly 24% of disease-causing
mutations in the Human Gene Mutation Database as of
November 2009 and have been shown to cause severe
phenotypic variability [31-33]. The inability of resequen-
cing arrays to have high sensitivity for detecting novel
indels, especially those involving only a few base pairs,
presents a significant limitation [10-12]. Regions show-
ing aberrant hybridization patterns can be selected for
confirmatory dideoxy sequencing to potentially detect
variations (including indels) that are missed with rese-
quencing arrays. However, as is evident from our data,
small indels present challenges as they sometimes do
not lead to easily discernible variability in hybridization
patterns. After interrogating three different deletions on
our arrays, we could detect only the largest deletion
through a series of no-calls and a variant call in the
region. Further algorithmic and technical improvements
could entail development of a scheme for detection of
indels by virtue of identifying a regional drop in signal
intensity. Although we only observed a single intensity
drop for one of the indels included in our validation,
modification of the technical protocol to limit the sec-
ondary amplification of signal, originally employed to
increase detection of low level transcripts in expression
arrays, may not be necessary for resequencing arrays
interrogating germline nuclear DNA variations present
with at least 50% signal compared to wildtype. This pro-
tocol modification could lead to better discrimination of
signal intensity drops across regions with an indel. In
t h ei n t e r i m ,w eh a v ee m p l o y e dclinical oligo hybridiza-
tion based sequencing technology only for diseases in
which most mutations are substitutions (e.g. Noonan
syndrome, cardiomyopathy) or the disease is recessive
(e.g. hearing loss) in which detection is aimed at finding
at least one of the pathogenic variants followed by capil-
lary sequencing of the relevant gene to detect a second
mutation that may have been missed.
Although a minor loss in analytical sensitivity is
incurred through the use of hybridization based sequen-
cing, this can be balanced with the increased efficiency
and diminished cost of this technology compared to tra-
ditional approaches. Resequencing array-based mutation
detection has been reported to produce a throughput of
nearly 100 patients per technician per month and can
thus be used as a method for initial genetic screening
while being supplemented with conventional dideoxy
sequencing for samples in which the array cannot iden-
tify a causative mutation [13]. In our hands, this tech-
nology has allowed us to cut the cost of testing roughly
in half compared to dideoxy capillary sequencing
approaches also employed in our clinical laboratories.
As such, we have now implemented this technology in
four different clinical tests including the HCM Cardio-
Chip, DCM CardioChip, Noonan Spectrum Chip, and
OtoChip as described on http://pcpgm.partners.org/
lmm.
Conclusions
In conclusion, the described hearing loss gene chips
represent the first resequencing arrays for molecular
testing of nonsyndromic pediatric SNHL. Using the
experimental protocols and additional computation
algorithms described here, this technology provides a
rapid, cost-effective and reasonably accurate method for
identifying known and novel sequence variants in tar-
geted DNA regions. However, follow-up sequencing
required to resolve no-calls and false positives does limit
the cost-effectiveness of the technology.
Methods
Patient enrolment
All 74 patient samples and clinical information were
collected under IRB-approved protocols. Most cases (66)
were recruited from clinical centers: 25 patients from
Ohio (J. Greinwald), 20 from Massachusetts (H. Rehm
and M. Kenna), 12 from Belgium (G. Van Camp), 5
from Israel (K. Avraham), 2 from Iowa (R. Smith), 2
from Nebraska (P. Kelley), and the remaining 8 repre-
sented anonymized samples obtained through clinical
testing at the Laboratory for Molecular Medicine at the
Partners Center for Personalized Genetic Medicine. All
patients had previously tested negative for biallelic GJB2
mutations, except for 3 patients who had heterozygous
mutations in the GJB2 gene. All patients had bilateral
SNHL and were either recessive cases (e.g. with affected
siblings) or singletons. DNA and clinical information
was collected on most patients (de-identified clinical
information for those cases that were anonymized) and
included demographic information, audiometric profiles,
family history, neuro-otologic history and physical
examinations.
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To determine what genes to place on a finite resequen-
cing platform that was initially capable of accommodat-
ing less than 27,000 bp, we undertook a comprehensive
literature search to estimate the likely frequency of
mutations in genes known to cause childhood SNHL.
Based on the prevalence of mutations in published
populations and family studies, the inheritance pattern
(s) of mutations (i.e. preference for recessive childhood
hearing loss) and the impact of the gene on patient out-
come (e.g. blindness developed due to Usher Syndrome),
an initial set of genes were selected for inclusion on one
or both hearing loss arrays (e.g. GJB2, GJB6, CDH23,
KCNE1, KCNQ1, MYO7A, OTOF, USH1C,a n d
TMPRSS3). Due to space limitations only the most con-
served portion of CDH23 was tiled. Most other genes
had extremely limited data on relative contribution and
therefore several genes were selected based upon other
minor characteristics (e.g. contribution to both domi-
nant and recessive hearing loss (e.g. MYO6), interest in
discovering a larger undocumented role in hearing loss
(e.g. SLC26A5) and/or small gene size to fill remaining
capacity on array (e.g. TMIE). It should be noted that
current studies suggest that SLC26A5 mutations may
n o tb eac a u s eo fh e a r i n gl o s s[ 3 4 ] .D e t a i l so ft h e
sequences included are in the Methods and Additional
file 1.
Two arrays were designed, one at University of Cincin-
nati/Children’s Hospital Medical Center (Cincinnati, OH)
and one at Harvard Medical School (Boston, MA) with 8
genes on each array representing a total of 13 unique
genes assessed. The Cincinnati array contained: GJB2,
GJB6, CDH23 (59 out of 69 exons; 80.3% of the coding
sequence), KCNE1, KCNQ1, MYO7A, OTOF,a n d
SLC26A4 genes and the Harvard array contained: GJB2,
MYO6, MYO7A, OTOF, SLC26A5, TMIE, TMPRSS3, and
USH1C genes. For all genes, both the coding sequence
and splice junctions were assessed. For the Cincinnati
array, 2 bp of each flanking splice site were tiled for most
exons. For the Harvard array, 10 bp of each flanking splice
site were tiled for all exons. Additional file 1 contains an
overview of the genes tiled on the arrays. Each array con-
tained probes to interrogate roughly 26,000 bases of DNA
(8 probes representing all 4 bases to assess the forward
strand and all 4 bases to assess the reverse strand). In
addition, probes designed to detect 17 previously reported
insertions and deletions were also tiled on the Harvard
array (Additional file 1).
Array protocol
Initially the arrays were run according to the manufac-
turer’s protocol (Affymetrix, Santa Clara, CA). Briefly,
long range PCR conditions for the LA TaKaRa Polymer-
ase (Takara, Japan) were: TaKaRa LA Taq 0.05 U/ul, 1×
LA PCR Buffer II, 400 uM (each) dNTPs, 0.3 uM (each)
primers, 4 ng/ul genomic DNA in a 25 ul reaction
volume. Short range PCR conditions are described
below for dideoxy sequencing. Cycling conditions for
most reactions were 94°C 2 min, (94°C 15 sec, 68°C 9
min) × 30, 68°C 14 min, 4°C. Modifications using stan-
dard approaches to PCR optimization were made for
some difficult reactions. All PCR assays were either
quantified using PicoGreen (Molecular Probes, Eugene,
OR) or absorbance spectrometry and then pooled in
equimolar amounts. The PCR products were then puri-
fied, fragmented, labeled and hybridized to the array.
Finally, the arrays were washed and scanned and the
data were analyzed using the GeneChip DNA Analysis
Software (GDAS 2.0, Affymetrix) or the GeneChip
Sequence Analysis Software (GSEQ 4.0, Affymetrix).
After initial experience, the Cincinnati protocol was
modified to include only short range PCR in order to
increase PCR and fragmentation consistency and facili-
tate the use of automation. In addition, PCR products
were cleaned robotically using magnetic beads, 7.5× less
fragmentation reagent was used than suggested (0.02 U
vs the recommended 0.15 U) and fragmentation pro-
ducts were analyzed using an Agilent Bioanalyzer (Santa
Clara, CA).
Dideoxy DNA sequencing protocol
Complete dideoxy sequencing of all exons was per-
formed for 14 of the Harvard patient arrays and all of
the 25 Cincinnati arrays (enabling assessment of false
negative rates) and partial sequencing was performed for
the remaining 35 patients in order to confirm or clarify
b a s e sa s s i g n e da sv a r i a n t so r“no calls” by Affymetrix
GDAS or GSEQ software. PCR conditions: AmpliTaq
Gold (Applied Biosystems, Foster City, CA) 0.05 U/ul,
1× ABI PCR Buffer, 2.5 mM MgCl2, 400 uM (each)
dNTPs, 0.4 uM (each) primers, 2 ng/ul genomic DNA
in a 25 ul reaction volume. Modifications using stan-
dards approaches to PCR optimization have been made
for some difficult reactions. Cycling conditions are 94°C
2 min, (94°C 15 sec, 60°C 30 sec, 72°C 30 sec) × 30, 72°
C 10 min, 4°C. Sequencing reactions are performed
using the same primers for short-range PCR (or internal
primers for long-range) in the following conditions: 0.25
μl Big Dye 3.1 (Applied Biosystems), 3.75 μl5 ×B i gD y e
Buffer, 0.50 μl DMSO, 2 μl1 0μM primer, 2 ul template
(1-5 ng) in 10 μl total volume. Cycle sequencing condi-
tions are 94°C 4 min, (98°C 30 sec, 50°C 5 sec, 60°C 4
min) × 30, 4°C. Reactionsa r ec l e a n e du pu s i n g
CleanSEQ magnetic beads (Agencourt Biosciences Corp,
Beverly, MA) and then run on an ABI 3730 DNA Ana-
lyzer (Applied Biosystems). Chromatograms are analyzed
using an automated Phred analysis program to check for
quality followed by analysis using Sequencher 4.0
Kothiyal et al. BMC Biotechnology 2010, 10:10
http://www.biomedcentral.com/1472-6750/10/10
Page 9 of 11(GeneCodes, Ann Arbor, MI) and/or Mutation Surveyor
(SoftGenetics, State College, PA) software.
Data analysis
Affymetrix GDAS 2.0 with optimized settings (Addi-
tional file 1) was used for assignment of base calls for
Harvard arrays and GSEQ 4.0 was used for Cincinnati
arrays. The algorithm settings were determined after
evaluating different quality score thresholds and com-
paring array calls with dideoxy sequencing results to
characterize coverage and accuracy. The settings cho-
sen were optimized for the highest call rate without
increasing the false negative rate. We also developed a
novel algorithm (sPROFILER) for strand-specific probe
cell intensity comparison for filtering GDAS/GSEQ
base calls. The algorithm was developed to re-examine
GDAS/GSEQ output to reduce no-calls and, in some
cases, false positives. sPROFILER attempts to resolve
no-calls based on intensity signature from a single
strand when a base cannot be called due to poor
hybridization on one of the strands. The algorithm
uses all wild-type bases within the array to determine
threshold for peak to next highest intensity ratio on
either strand and uses the base call at the position of
interest across all arrays to determine the proportion
of wild-type calls that are made on that position by
GSEQ. The latter is used for scaling the threshold
ratio and thus, in effect, making the algorithm more
conservative while attempting to assign a wild-type call
to a position that is being called variant in a large
number of samples and vice-versa. We also adopted
two additional bioinformatics filters developed for the
Francisella tularensis whole-genome resequencing plat-
form [17]. The filters were designed for reduction in
false positives by screening variant calls that 1) are in
regions rich in variant calls and no-calls, and 2) have
low quality scores for the corresponding base call.
With the exception of wild-type calls within no-call
stretches, sPROFILER does not attempt to re-examine
any base calls conforming to the reference sequence
because GDAS and GSEQ are conservative in making
wild-type calls and thus achieve low false negative
rates. The output calls were compared against sequen-
cing results and against GDAS/GSEQ calls for valida-
tion. sPROFILER was implemented in MATLAB. A
detailed description of sPROFILER and accompanying
MATLAB code are provided in Additional files 1 &2.
Additional file 1: Supplementary data. Provides accession numbers for
genomic sequences tiled on the arrays, GDAS/GSEQ algorithm settings
used for the analysis, a list of variants identified in hearing loss probands,
and a detailed description of the sPROFILER algorithm.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6750-10-
10-S1.PDF]
Additional file 2: sPROFILER code. Provides MATLAB code for
sPROFILER, a novel algorithm implemented for improving array call rates.
Provides a list of genes tiled on the arrays, variants identified in hearing
loss probands, and a detailed description of the sPROFILER algorithm.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-6750-10-
10-S2.TXT]
Abbreviations
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